13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001388325
Total reported value
$1.7B
$1.7B
31 檔
41.1%
According to the latest 13F quarterly dataset, Novo Holdings A/S managed an equity portfolio of $1.7B at the end of Q1 2025, spanning 31 distinct U.S. exchange-listed positions.
In Q1 2025, Novo Holdings A/S displayed an active expansion posture, initiating 31 new positions and adding to 0 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | VTI | Vanguard Total Stock Mkt ETF | ETF-Other | 21.71% | — | — | |
| 2 | BN | Brookfield CORP | Stock-Financials | 9.29% | -2.78% | -16.72% | |
| 3 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 8.95% | -1.03% | +7.00% | |
| 4 | ASML | ASML Holding N.V. | Stock-Tech | 8.36% | +0.81% | — | |
| 5 | CRM | Salesforce Inc | Stock-Tech | 5.57% | -2.37% | -7.18% | |
| 6 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 5.14% | -2.27% | — | |
| 7 | INSM | Insmed Inc | Stock-Healthcare | 4.21% | +0.75% | NEW | |
| 8 | RXRX | Recursion Pharmaceuticals-a | Stock-Healthcare | 3.89% | — | -4.44% | |
| 9 | BABA | Alibaba Group Holding-sp Adr | Stock-Consumer Disc | 3.75% | -1.19% | -17.69% | |
| 10 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 3.25% | -1.69% | +32.78% | |
| 11 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 2.63% | -3.02% | EXIT | |
| 12 | AVBP | Arrivent Biopharma Inc | Stock-Other | 2.63% | -0.60% | +23.12% | |
| 13 | PCVX | Vaxcyte Inc | Stock-Other | 2.63% | -1.35% | +22.00% | |
| 14 | ✓ | Merus N V | Stock-Other | 2.53% | — | +5.22% | |
| 15 | VRDN | Viridian Therapeutics Inc | Stock-Other | 2.31% | -0.89% | +0.01% | |
| 16 | PHVS | Pharvaris N.V. | Stock-Other | 2.06% | -1.20% | — | |
| 17 | AM6 | Amicus Therapeutics Inc | Stock-Other | 1.71% | — | +10.00% | |
| 18 | CLDX | Celldex Therapeutics Inc | Stock-Other | 1.66% | -0.87% | +20.00% | |
| 19 | 2655787D | Blueprint Medicines CORP | Stock-Other | 1.54% | — | +30.75% | |
| 20 | ZBIO | Zenas Biopharma Inc | Stock-Other | 1.33% | — | +38.44% | |
| 21 | CBLL | Ceribell Inc | Stock-Other | 1.29% | — | +167.63% | |
| 22 | ✓ | Verve Therapeutics Inc | Stock-Other | 1.04% | — | +25.00% | |
| 23 | RCKT | Rocket Pharmaceuticals Inc | Stock-Other | 0.56% | — | — | |
| 24 | FDMT | 4d Molecular Therapeutics In | Stock-Other | 0.48% | -0.24% | +30.00% | |
| 25 | LXEO | Lexeo Therapeutics Inc | Stock-Other | 0.30% | — | — | |
| 26 | ✓ | Lanzatech Global Inc | Stock-Other | 0.29% | — | — | |
| 27 | IOBTQ | Io Biotech Inc | Stock-Other | 0.28% | — | — | |
| 28 | KYTX | Kyverna Therapeutics Inc | Stock-Other | 0.27% | — | — | |
| 29 | ABCL | Abcellera Biologics Inc | Stock-Other | 0.19% | — | — | |
| 30 | MQ | Marqeta Inc-a | Stock-Other | 0.14% | +0.27% | — | |
| 31 | DMRA | Damora Therapeutics Inc | Stock-Other | 0.02% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | VTI | Vanguard Total Stock Mkt ETF | — | NEW | New buy |
| 2 | BN | Brookfield CORP | — | NEW | New buy |
| 3 | EWTX | Edgewise Therapeutics Inc | — | NEW | New buy |
| 4 | ASML | ASML Holding N.V. | — | NEW | New buy |
| 5 | CRM | Salesforce Inc | — | NEW | New buy |
| 6 | MIRM | Mirum Pharmaceuticals Inc | — | NEW | New buy |
| 7 | INSM | Insmed Inc | — | NEW | New buy |
| 8 | RXRX | Recursion Pharmaceuticals-a | — | NEW | New buy |
| 9 | BABA | Alibaba Group Holding-sp Adr | — | NEW | New buy |
| 10 | CRNX | Crinetics Pharmaceuticals In | — | NEW | New buy |
| 11 | BMRN | Biomarin Pharmaceutical Inc | — | NEW | New buy |
| 12 | AVBP | Arrivent Biopharma Inc | — | NEW | New buy |
| 13 | PCVX | Vaxcyte Inc | — | NEW | New buy |
| 14 | ✓ | Merus N V | — | NEW | New buy |
| 15 | VRDN | Viridian Therapeutics Inc | — | NEW | New buy |
| 16 | PHVS | Pharvaris N.V. | — | NEW | New buy |
| 17 | AM6 | Amicus Therapeutics Inc | — | NEW | New buy |
| 18 | CLDX | Celldex Therapeutics Inc | — | NEW | New buy |
| 19 | 2655787D | Blueprint Medicines CORP | — | NEW | New buy |
| 20 | ZBIO | Zenas Biopharma Inc | — | NEW | New buy |
| 21 | CBLL | Ceribell Inc | — | NEW | New buy |
| 22 | ✓ | Verve Therapeutics Inc | — | NEW | New buy |
| 23 | RCKT | Rocket Pharmaceuticals Inc | — | NEW | New buy |
| 24 | FDMT | 4d Molecular Therapeutics In | — | NEW | New buy |
| 25 | LXEO | Lexeo Therapeutics Inc | — | NEW | New buy |
| 26 | ✓ | Lanzatech Global Inc | — | NEW | New buy |
| 27 | IOBTQ | Io Biotech Inc | — | NEW | New buy |
| 28 | KYTX | Kyverna Therapeutics Inc | — | NEW | New buy |
| 29 | ABCL | Abcellera Biologics Inc | — | NEW | New buy |
| 30 | MQ | Marqeta Inc-a | — | NEW | New buy |
| 31 | DMRA | Damora Therapeutics Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Novo Holdings A/S reported a total U.S. public equity portfolio value of $1.7B across 31 disclosed positions in Q1 2025.
During Q1 2025, Novo Holdings A/S's top holdings by market value included VTI (21.7%)、BN (9.3%)、EWTX (8.9%). The largest single position, VTI, represented 21.7% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including VTI, BN, EWTX) accounted for 41.1% of total reported equity market value during Q1 2025.
Top New Position Initiated
VTI
市值: $285.4M
In Q1 2025, Novo Holdings A/S made 31 total portfolio adjustments, initiating 31 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.